Quantcast

Latest Intravenous immunoglobulin Stories

2009-01-06 12:09:00

Patients with this Pediatric Disease Depend on Plasma Donation ANNAPOLIS, Md., Jan. 6 /PRNewswire/ --Kawasaki disease is an uncommon illness that typically affects children between the ages of two and five and is a leading cause of acquired heart disease in children in the United States according to the American Heart Association (AHA). Kawasaki disease is treated with intravenous immune globulin (IVIG), a plasma-derived therapy that replaces vital missing antibodies in a person's plasma and...

2008-12-23 14:44:24

Implications for new tests and more personalized treatments for autoimmune diseases More drafts usually mean a better product and so it also seems to go with the human immune system. As B cells develop, genes rearrange to allow their antibodies to recognize different foreign invaders or pathogens. But sometimes antibodies are created that recognize and attack the body's own cells. These self-reactive antibodies, like early drafts of a manuscript, must be edited into safer versions. This...

2008-12-04 10:00:00

ATLANTA and LACHEN, Switzerland, Dec. 4 /PRNewswire/ -- Octapharma Chairman Wolfgang Marguerre today announced that Dennis D. Curtin has been selected to lead Octapharma's plasma operations in the United States. Curtin had been Octapharma's U.S. legal counsel since 2002 and will now serve as President of Life Therapeutics, Inc. The largest private plasma products company in the world, Octapharma recently acquired Life Therapeutics, the Atlanta company that operates 12 plasma centers...

2008-10-27 12:00:10

PROVIDENCE, R.I., Oct. 27 /PRNewswire/ -- Dr. Annie De Groot, CEO of EpiVax, is the lead author on an article highlighting key findings about the activation of natural regulatory T cells by IgG Fc-derived peptide, also known as Epi-13 or "Tregitopes." These findings were published in the October 8 issue of the prestigious Blood, the medical journal published by the American Society of Hematology. In an accompanying editorial, Rachel Caspi of the National Institutes of Health (NIH) wrote,...

2008-10-15 12:00:33

Under a new program introduced by Talecris Biotherapeutics, patients who regularly use Gamunex (Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified) may be able to receive continuing treatment in the event of a lapse in private insurance coverage. Gamunex is an immunoglobulin intravenous (IGIV) therapy that contains antibodies purified from the donated blood plasma of thousands of people. Gamunex is indicated as replacement therapy of primary humoral...

1c523d2e77856dd428c5e894475426621
2008-10-14 11:05:00

Every one in three patients needing a kidney transplant may never receive one because their bodies are unusually conditioned to assault a donated organ. Doctors are now trying to outsmart the immune system and save more "highly sensitized" patients. These patients often have kidneys donated by living donors, thought to be the best kind. "I feel very lucky. Our son saved my life," said Cynthia Preloh, after a curious mixture of blood cleansing and a cancer drug permitted her to accept a...

2008-09-23 12:00:13

A study of a treatment for chronic inflammatory demyelinating neuropathy (CIDP) suggests that 50 percent of the patients who responded to treatment with Gamunex (Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified) required two treatments before they first exhibited improvements on a standard disability measurement scale, according to data presented at the American Neurological Association meeting in Salt Lake City, Utah. The study authors concluded that "further...

2008-09-15 09:00:11

The FDA has approved Talecris Biotherapeutics's Gamunex, an immune globulin product for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare autoimmune disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The FDA designated Gamunex as an orphan drug to treat chronic inflammatory demyelinating polyneuropathy (CIDP). The FDA based its approval of Gamunex on clinical trials that showed Gamunex was effective at improving...

2008-09-15 09:00:11

Talecris Biotherapeutics, Inc. announced today the U.S. Food and Drug Administration (FDA) has granted approval for Gamunex (Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified) as a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a debilitating neurological disorder that results in muscle weakness and fatigue, which can lead to severe impairment of motor skills. Through its approval, Gamunex is the only therapy of any kind with an...

2008-09-05 09:00:08

Biotech company Pharming Group has announced that the FDA has authorized a clinical study with recombinant human C1 inhibitor for the treatment of antibody-mediated rejection in kidney transplantation. Hans Sollinger of the University of Wisconsin, Madison will conduct the clinical trial with recombinant human C1 inhibitor (rhC1INH) under an investigator IND from the FDA. Recombinant human C1 inhibitor is a key inhibitor of the classical complement system. In the planned study, rhC1INH...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related